Administrative databases are widely available and have been extensively used to provide estimates of chronic disease prevalence for the purpose of surveillance of both geographical and temporal trends. There are, however, other sources of data available, such as medical records from primary care and national surveys. In this paper we compare disease prevalence estimates obtained from these three different data sources.

Clinical Decision Support Systems (CDSSs) are computer-based tools intended to support physicians in clinical decision making. MilleDSS is an illustrative example for the Italian context. It is featured by four domains of GP-software interaction, such as clinical management and follow-up evaluation, prescribing appropriateness and clinical risk, prevention strategies and medical computerized stewardship on scientific update and training. MilleDSS registered 23,222 accesses in early September 2021. In specific, the sections on prevention and training were viewed 19,440 and 21,797 times, respectively. The Medical Device Regulation (MDR: (EU) 2017/745) indicates that clinical evidence needs to be provided for any software intended to medical purpose. Clinical research on CDSS effectiveness will be therefore conducted through epidemiological studies. In theory, this generation of evidence would follow the pyramid of evidence as per medications approval but, given the large use and constant update of CDSS for daily clinical practice, attentions should be posed on the most cost-effective study.

The General Practitioner (GP) is the “gate-keeper” in patients' treatment and management. Herein, the use of Electronic Medical Records (EMR) could represent an effective support for GPs. Software capable of managing EMRs are available and they can be functional in adopting treatment guidelines by means of computerized prompts and reminders systems. These tools can be also programmed to include clinical algorithms with which to measure the quality of care to make possible the identification of clinical issues, and to take actions for addressing them. Given that similar tools were not available in Italy, we developed MilleGPG, an interactive tool aimed to evaluate, and subsequently improve the quality of care among patients with comorbidities.

Background: In recent years, Europe has experienced a significant increase in pertussis cases. One reason behind this rise is the decline in diphtheria–tetanus–pertussis (dTap) booster coverage among adults. Currently, Italy lacks a reliable monitoring system to track pertussis infections and vaccine coverage among adults. We therefore evaluated the reliability of a primary care framework to respond to this need. Methods: Using an Italian primary care database for individuals aged 15 or above, we determined the pertussis infection notification rate and dTap vaccine/booster coverage for the timeframe of 2009–2022. Results: In the overall population, we obtained a lifetime occurrence rate of pertussis infections of 7.52 per 10,000 individuals. The annual incidence rates of pertussis infections ranged from 0.008 to 0.001 per 10,000 person-years between 2009 and 2022. A rising trend in dTap vaccine coverage rate (ranging from 8.72 to 16.54 vaccines per 10,000 individuals) was observed during the same period. Notably, those aged 65 or older, smokers, and/or individuals with immunodeficiencies were more likely to receive the dTap vaccine compared to the general population. Conclusions: Given the organization of the Italian public health system, this primary care network might act as a reliable epidemiological monitoring system to keep track of pertussis infections and dTap vaccine coverage in adults. Pertussis cases were underreported, and there was a low uptake of vaccines and boosters. Therefore, it is crucial to closely monitor pertussis notifications and dTap administrations and develop intervention strategies at the national level to enhance vaccine-related prevention.